Infectious Disease Topics
RSSArticles
-
Combination Therapy for Invasive Aspergillosis in Patients with Hematologic Malignancies or Hematopoeitic Cell Transplants
In an evaluation of the primary endpoint, all-cause mortality at 6 weeks, there was no statistically significant difference between treatment with voriconazole alone or in combination with anidulafungin in patients with invasive aspergillosis and hematologic malignancies or hematopoietic stem cell transplants.